Teledoc rallies in pre-market after being named a ‘surefire growth stock’
Teladoc Health (TDOC) is +1.4% in pre-market trading as Motley Fool author, Danny Vena, names it as among ‘3 Surefire Growth Stocks to Buy Before 2021.’Citing the company’s exponential revenue growth, and the recent
Seekingalpha · 12/21/2020 14:31
Livongo Health Q3 2020 Earnings Preview
Livongo Health (NASDAQ:LVGO) is scheduled to announce Q3 earnings results on Wednesday, October 28th, after market close.The consensus EPS Estimate is $0.06 (+220.0% Y/Y) and the consensus Revenue Estimate is
Seekingalpha · 10/27/2020 21:35
Medical Products Q3 Earnings on Oct 28: BSX, CERN & More
In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.
Zacks · 10/27/2020 16:48
Livongo Health (LVGO) to Post Q3 Earnings: What's in Store?
Livongo Health's (LVGO) third-quarter results are likely to reflect growth in core Livongo for Diabetes solution.
Zacks · 10/26/2020 12:00
Jim Cramer reviews top 10 winners on his Cramer Covid-19 index
"Since we created the Cramer Covid-19 index six months ago, the stay-at-home, work-at-home stocks just have not been able to quit," the "Mad Money" host said. · 10/23/2020 23:01
Jim Cramer reviews top 10 winners on his Cramer Covid-19 index
"Since we created the Cramer Covid-19 index six months ago, the stay-at-home, work-at-home stocks just have not been able to quit," the "Mad Money" host said. · 10/23/2020 23:01
Livongo Health (LVGO) Reports Next Week: Wall Street Expects Earnings Growth
Livongo Health (LVGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 10/21/2020 17:32
Livongo Health (LVGO) Stock Sinks As Market Gains: What You Should Know
Livongo Health (LVGO) closed at $142.75 in the latest trading session, marking a -0.39% move from the prior day.
Zacks · 10/20/2020 21:45
Livongo signs strategic partnership in care delivery
Livongo ([[LVGO]] -0.2%) announces strategic partnership with GuideWell Mutual Holding's Florida Blue for proven chronic condition management solution to its members.Under this partnership, Livongo together with Teladoc will offer select Florida Blue members
Seekingalpha · 10/16/2020 16:34
GuideWill Reports Strategic Deal With Livongo
GuideWell Mutual Holding Corporation (GuideWell), the parent to a family of forward-thinking companies focused on transforming health care, announced a strategic agreement today with Livongo (NASDAQ:LVGO) the leading
Benzinga · 10/16/2020 16:11
Livongo to Release Results for the Third Quarter of Fiscal Year 2020
MOUNTAIN VIEW, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Livongo Health, Inc., (Nasdaq: LVGO) today announced it will release its financial results for its third quarter of fiscal year 2020 on October 28, 2020, after close of the U.S. stock market. Given the pending transaction with Teladoc Health, Livongo is not hosting a conference call in conjunction with its third quarter of 2020 earnings release. About LivongoLivongo empowers people with chronic conditions to live better and healthier lives, beginning with diabetes and now including hypertension, weight management, diabetes prevention, and behavioral health. Livongo pioneered the category of Applied Health Signals to offer Members clinically-based insights that focus on the whole person and make it easier to stay healthy. Using its AI+AI engine, Livongo’s team of data scientists aggregate and interpret substantial amounts of health data and information to create actionable, personalized and timely health signals delivered to Livongo Members exactly when and where they need them. The Livongo approach delivers better clinical and financial outcomes while creating a different and better experience for people with chronic conditions. For more information, visit: or engage with Livongo on LinkedIn or Twitter.Cautionary Note Regarding Forward-Looking StatementsThis communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the potential transaction between Teladoc and Livongo, including any statements regarding the expected timetable for completing the potential transaction, the ability to complete the potential transaction, the expected benefits of the potential transaction (including anticipated synergies, projected financial information and future opportunities) and any other statements regarding Teladoc’s and Livongo’s future expectations, beliefs, plans, objectives, results of operations, financial condition and cash flows, or future events or performance. These statements are often, but not always, made through the use of words or phrases such as “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar expressions. All such forward-looking statements are based on current expectations of Teladoc’s and Livongo’s management and therefore involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking statements include the ability to obtain the requisite Teladoc and Livongo stockholder approvals; uncertainties as to the timing to consummate the potential transaction; the risk that a condition to closing the potential transaction may not be satisfied; the risk that the anticipated U.S. federal income tax treatment of the transaction is not obtained; litigation relating to the potential transaction that have been or could be instituted against Teladoc, Livongo or their respective directors; the effects of disruption to Teladoc’s or Livongo’s respective businesses; restrictions during the pendency of the potential transaction that may impact Teladoc’s or Livongo’s ability to pursue certain business opportunities or strategic transactions; the effect of this communication on Teladoc’s or Livongo’s stock prices; transaction costs; Teladoc’s ability to achieve the benefits from the proposed transaction; Teladoc’s ability to effectively integrate acquired operations into its own operations; the ability of Teladoc or Livongo to retain and hire key personnel; unknown liabilities; and the diversion of management time on transaction-related issues. Other important factors that could cause actual results to differ materially from those in the forward-looking statements include the effects of industry, market, economic, political or regulatory conditions outside of Teladoc’s or Livongo’s control (including public health crises, such as pandemics and epidemics); changes in laws and regulations applicable to Teladoc’s business model; changes in market conditions and receptivity to Teladoc’s services and offerings; results of litigation; the loss of one or more key clients of Teladoc (including potential adverse reactions or changes to business relationships resulting from the announcement or completion of the potential transaction); changes to Teladoc’s abilities to recruit and retain qualified providers into its network; the impact of the COVID-19 pandemic on the parties’ business and general economic conditions; risks regarding Livongo’s ability to retain clients and sell additional solutions to new and existing clients; Livongo’s ability to attract and enroll new members; the growth and success of Livongo’s partners and reseller relationships; Livongo’s ability to estimate the size of its target market; uncertainty in the healthcare regulatory environment; and the factors set forth under the heading “Risk Factors” of Teladoc’s Annual Report and Livongo’s Annual Report, in each case on Form 10-K, and in subsequent filings with the U.S. Securities and Exchange Commission (the “SEC”). These risks, as well as other risks associated with the potential transaction, are more fully discussed in the joint proxy statement/prospectus filed with the SEC in connection with the proposed transaction. Other unpredictable or unknown factors not discussed in this communication could also have material adverse effects on forward-looking statements. Neither Teladoc nor Livongo assumes any obligation to update any forward-looking statements, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.No Offer or SolicitationThis communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.Important Information for Investors and StockholdersIn connection with the potential transaction, Teladoc has filed a registration statement on Form S-4 (File No. 333-248568) with the SEC containing a prospectus of Teladoc that also constitutes a definitive joint proxy statement of each of Teladoc and Livongo. The registration statement, as amended, was declared effective by the SEC on September 15, 2020. Each of Teladoc and Livongo commenced mailing copies of the definitive joint proxy statement/prospectus to stockholders of Teladoc and Livongo, respectively, on or about September 15, 2020. Teladoc and Livongo may also file other documents with the SEC regarding the potential transaction. This communication is not a substitute for the joint proxy statement/prospectus or registration statement or for any other document that Teladoc or Livongo have filed or may file with the SEC in connection with the potential transaction. INVESTORS AND SECURITY HOLDERS OF TELADOC AND LIVONGO ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT ARE FILED OR WILL BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the joint proxy statement/prospectus and other documents filed with the SEC by Teladoc or Livongo through the website maintained by the SEC at Copies of the documents filed with the SEC by Teladoc will be available free of charge on Teladoc’s website at and copies of the documents filed with the SEC by Livongo will be available free of charge on Livongo’s website at Additionally, copies may be obtained by contacting the investor relations departments of Teladoc or Livongo.Teladoc and Livongo and certain of their respective directors, certain of their respective executive officers and other members of management and employees may be considered participants in the solicitation of proxies with respect to the potential transaction under the rules of the SEC. Information about the directors and executive officers of Teladoc is set forth in its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on April 14, 2020. Information about the directors and executive officers of Livongo is set forth in its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the SEC on March 24, 2020, and its proxy statement for its 2020 annual meeting of stockholders, which was filed with the SEC on April 6, 2020. These documents can be obtained free of charge from the sources indicated above. Additional information regarding the interests of such participants in the solicitation of proxies in respect of the potential transaction are included in the registration statement and joint proxy statement/prospectus and other relevant materials filed with the SEC.The term “Livongo” and such terms as “the company,” “the corporation,” “our,” “we,” “us” and “its” may refer to Livongo Health, Inc., one or more of its consolidated subsidiaries, or to all of them taken as a whole. All of these terms are used for convenience only and are not intended as a precise description of any of the separate companies, each of which manages its own affairs.Investor Contact: Jason Plagman 785-550-6048Media Contact: John Hallock 617-615-7712
GlobeNewswire · 10/15/2020 13:05
Livongo Health (LVGO) Stock Moves -0.43%: What You Should Know
Livongo Health (LVGO) closed at $147.44 in the latest trading session, marking a -0.43% move from the prior day.
Zacks · 10/14/2020 22:45
JP Morgan Downgrades Livongo Health to Neutral, Raises Price Target to $150
JP Morgan downgrades Livongo Health (NASDAQ:LVGO) from Overweight to Neutral and raises the price target from $88 to $150.
Benzinga · 10/14/2020 09:16
Recovery stocks battered, but tech holding level
The market is reverting to its pattern earlier this year where Big Tech is a safety and recovery stocks are getting slammed.Today that's translating to broader weakness and a slight
Seekingalpha · 10/13/2020 17:34
Toddler Portfolio Q2 2020 Results
Infant Portfolio update. Q2 2020 results are in.Infant Portfolio becomes Toddler Portfolio.BAM Added.
Seekingalpha · 10/07/2020 16:08
This Hot New ETF Will Be Just Fine After COVID-19 Is Defeated
Plenty of new exchange-traded funds are coming to market this year and many have something in common: Leverage to the coronavirus pandemic.
Benzinga · 10/06/2020 15:35
Exclusive Interview: The Motley Fool Sits Down With Citus Health CEO · 10/05/2020 06:24
Project $1M: Livongo Health Brightens A Bleak September
The Project $1M portfolio saw its first decline in September since March 2020. September also marked the first notable decline versus the S&P 500 for 2020.I made a couple of portfolio changes in September, with the elimination of some long-standing positions, and the addition of a new position.Project $1M continues to meet my expectations, returning 23% p.a. since inception and 30% this year, well clear of the S&P 500 in both the short and medium term.
Seekingalpha · 10/05/2020 05:17
2 Coronavirus Trends That Are Starting to Subside · 10/03/2020 09:02
Market Crash 2.0: 3 Stocks to Save Your Portfolio · 10/03/2020 06:45
Webull provides a variety of real-time LVGO stock news. You can receive the latest news about Livongo Health through multiple platforms. This information may help you make smarter investment decisions.
About LVGO
Livongo Health, Inc. is a consumer digital health company. The Company offers Enter Livongo platform, which leverages data science and technology, creates a personalized experience for people with chronic conditions. The Company focuses on developing an approach for diabetes management that combines technology with coaching. The Company’s Livongo platform offers a range of solutions, such as Livongo for Diabetes, Livongo for Hypertension, Livongo for Prediabetes and Weight Management and Livongo for Behavioral Health by myStrength. The Company uses a digital approach to delivering evidence-based interventions including cognitive behavioral therapy, acceptance and commitment therapy, positive psychology, mindfulness, and motivational interviewing to help resolve clinical conditions, build resiliency, manage stress, improve mood, sleep better, or simply find daily inspiration.